Multiple Myeloma | Specialty

Upfront Therapy Approaches in Myeloma

January 23rd 2018

Managing High-Risk Smoldering Myeloma

January 23rd 2018

Risk Assessment for Myeloma

January 23rd 2018

FDA Grants Priority Review to Frontline Daratumumab for Multiple Myeloma

January 22nd 2018

The FDA has granted a priority review designation to daratumumab in combination with bortezomib, melphalan, and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.

Dr. Wolf Emphasizes the Importance of Maintenance Therapy in Patients With Myeloma

January 18th 2018

Jeffrey Wolf, MD, clinical professor, Department of Medicine, director, Myeloma Program, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, details the role maintenance therapy has in treating patients with myeloma.

Dr. Richter on Study of Symptom Management in Multiple Myeloma

January 18th 2018

Joshua Richter, MD, a hematologist/oncologist specializing in multiple myeloma at the John Theurer Cancer Center discusses symptom management in patients with multiple myeloma.

FDA Approves Carfilzomib Label Update in Myeloma

January 18th 2018

The FDA has approved a supplemental new drug application that adds overall survival data from the phase III ENDEAVOR trial to the label for carfilzomib for use in patients with relapsed or refractory multiple myeloma.

Emerging Therapies Generate Excitement in Myeloma

January 17th 2018

Thomas G. Martin, MD, discusses emerging advancements in the treatment landscape of multiple myeloma.

Dr. Martin on Choosing Treatments for Multiple Myeloma

January 16th 2018

Thomas G. Martin, MD, clinical professor of medicine, Adult Leukemia and Bone Marrow Transplantation Program, and associate director, Myeloma Program, University of California, San Francisco; co-leader, Hematopoietic Malignancies Program, Helen Diller Family Comprehensive Cancer Center, discusses choosing treatments for patients with multiple myeloma.

Dr. Gasparetto on Next Steps With Selinexor and Daratumumab in Multiple Myeloma

January 8th 2018

Cristina Gasparetto, MD, assistant professor of medicine, member of the Duke Cancer Institute, discusses the next steps with selinexor and daratumumab (Darzalex) in multiple myeloma.

Dr. Martin on FDA Approval of Denosumab in Multiple Myeloma

January 5th 2018

Thomas G. Martin, MD, clinical professor of medicine, Adult Leukemia and Bone Marrow Transplantation Program, and associate director, Myeloma Program, University of California, San Francisco; co-leader, Hematopoietic Malignancies Program, Helen Diller Family Comprehensive Cancer Center, discusses the FDA approval of denosumab (Xgeva) for the prevention of skeletal-related events in patients with multiple myeloma.

FDA Approves Denosumab for Multiple Myeloma

January 5th 2018

The FDA has approved denosumab (Xgeva) for the prevention of skeletal-related events in patients with multiple myeloma.

Dr. Pecora on CTLA-4 and PD-1 Combinations in Multiple Myeloma

January 3rd 2018

Andrew L. Pecora, MD, president of the Physician Services Division and chief innovation officer at Hackensack Meridian Health, discusses the combination of CTLA-4 and PD-1 inhibitors for the treatment of patients with multiple myeloma.

Dr. Usmani on the Gimema-MMY-3006 Study for Multiple Myeloma

December 21st 2017

Saad Z. Usmani, MD, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Carolinas HealthCare System, discusses the phase III Gimema-MMY-3006 study for patients with multiple myeloma.

Daratumumab Regimen Maintains Favorable Performance in Relapsed/Refractory Myeloma

December 21st 2017

Progression-free survival remained superior over time in patients with relapsed/refractory multiple myeloma treated treated with combination therapy that included the anti-CD38 antibody daratumumab (Darzalex).

NICE Recommends Ixazomib for Multiple Myeloma Through CDF

December 20th 2017

The United Kingdom's National Institute for Health and Care Excellence has issued guidance recommending ixazomib in for patients with relapsed/refractory multiple myeloma.

Dr. Gasparetto on Selinexor and Daratumumab Combination in Multiple Myeloma

December 19th 2017

Cristina Gasparetto, MD, assistant professor of medicine, member of the Duke Cancer Institute, discusses a phase Ib study of the combination of selinexor and daratumumab (Darzalex) in patients with relapsed/refractory multiple myeloma.

Selinexor Combo Highly Active in Relapsed/Refractory Myeloma

December 15th 2017

Selinexor combined with weekly bortezomib and low-dose dexamethasone produced rapid and durable responses in a dose escalation/expansion trial of patients with relapsed/refractory multiple myeloma.

Dr. Chari on Challenges in Sequencing Agents for Multiple Myeloma

December 14th 2017

Ajai Chari, MD, associate professor, Mount Sinai Hospital, discusses challenges in sequencing agents for patients with multiple myeloma.

New Analysis Confirms Carfilzomib Survival Benefit in Relapsed/Refractory Myeloma

December 14th 2017

The addition of carfilzomib to lenalidomide and dexamethasone for relapsed/refractory multiple myeloma led to a statistically significant 21% reduction in the risk for death compared with lenalidomide and dexamethasone.